Humanized Anti-BCMA Antibody BSI-022B used for malignant multiple myeloma
Seeking a collaborative licensing opportunity with a company that has a strategic interest in the treatment of malignant Multiple Myeloma (MM)
Field: Treatment for Cancer, especially for malignant Multiple Myeloma (MM)
Technology and MOA
MOA:B-cell maturation antigen (BCMA or BCM), also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a protein that in humans is encoded by the TNFRSF17 gene.
Anti-BCMA antibody exhibits antineoplastic activity by targeting cells expressing B-cell maturation antigen. BCMA plays a central role in regulating B-cell maturation and differentiation into plasma cells (PC) which accumulate in the bone marrow (BM) leading to the development of osteolytic bone lesions. It also promotes tumor cell survival. The therapeutic candidate binds to BCMA antigen on tumor cells and activates T cells and directs them to BCMA expressing tumor cells, stimulating a selective toxicity to tumor cells.
There remains an unmet need for patients with multiple myeloma (MM), particularly in the later-line settings, despite several new treatments and improved outcomes. Agents targeting the B-cell maturation antigen (BCMA) marker, which is highly specific for MM, could play a significant role in both relapsed/remitting MM (RRMM) and also earlier disease settings. MM is the second most common hematological cancer. Prevalence is increasing due to better diagnosis, an aging population and newer treatment options improving patient survival. Stem cell transplant plus high-dose chemotherapy is a first-line treatment option in younger and otherwise healthy MM patients. However, drug-based therapies are required in around 70% of patients not eligible for stem cell transplant.
Global market for Multiple Myeloma should reach $40.6 bn in 2025 from $18.74 bn in 2018 at a compound annual growth rate (CAGR) of 11.7%, from 2018 to 2025
The global therapeutic market to BCMA target should reach $4,448 M in 2025 GSK2857916’s net present value (NPV) is estimated about one billion USD by GlobalData
Differentiable treatment with potential to be first/ best in class
BSI-022B is a high-affinity humanized anti-BCMA monoclonal antibody molecule with significant higher internalization activity than benchmark – GSK2857916 (Belantamab mafodotin, GSK Inc) – recently approved.
• Refractory Multiple Myeloma;
• Relapsed Multiple Myeloma;
• Diffuse Large B-Cell Lymphoma;
• Follicular Lymphoma;
• Multiple Myeloma (Kahler Disease);
Key parameters of humanized anti-BCMA antibody BSI-022B as compared to GSK2857916:
• Higher affinity to huBCMA with fast Kon and fast Koff binding kinetics
• Antibody internalization activity is 8-fold higher than that of GSK2857916
• Overlapped epitope as GSK2857916
• An ideal candidate for next generation BCMA-ADC development
For discussion under CDA.